open access

Vol 20, No 2 (2013)
Original articles
Published online: 2013-04-05
Get Citation

Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol

Jadwiga Nessler, Bohdan Nessler, Renata Golebiowska-Wiatrak, Ilona Palka, Andrzej Gackowski, Mariusz Kitlinski, Olle Melander, Artur Fedorowski
DOI: 10.5603/CJ.2013.0027
·
Cardiol J 2013;20(2):144-151.

open access

Vol 20, No 2 (2013)
Original articles
Published online: 2013-04-05

Abstract

Background: The role of infl ammatory and hemodynamic stress biomarkers in heart failure
(HF) patients treated de novo with beta-blockers has been poorly studied.

Methods: A total of 86 patients (age 56 ± 9 years, 81 men) with left ventricular ejection fraction
(LVEF) < 40% and previously not treated with beta-blockers were initiated on carvedilol.
At baseline and 12 months later we performed echocardiography, cardiopulmonary exercise
testing, and determined serum levels of B-type natriuretic peptide (BNP), endothelin-1 (ET-1),
C-reactive protein (CRP), interleukin-6, and tumor necrosis factor alpha (TNF -a). Patients
were followed up over a total period of 9 ± 3 years from baseline.

Results: Increased baseline CRP and its on-treatment decrease were associated with improvement
of LVEF (est. coeffi cient per one SD: 1.6; 95% CI: –0.05,3.28; p = 0.056, and –1.80;
–3.43, –0.18; p = 0.030, respectively) and diminishing of LV end-systolic volume index
[mL/m2] (–6.83; –11.32; –2.34; p = 0.003, and 5.85; 1.23; –10.46; p = 0.014, respectively).
Higher baseline ET-1 and on-treatment increase in TNF-a predicted frequent admissions
(> 1) for cardiac complications (odds ratio per one SD: 1.98; 95% CI: 1.09–3.59;
p = 0.025, and 2.07, 1.12–3.84, p = 0.021, respectively) whereas higher baseline BNP was
asociated with increased mortality (hazard ratio per one SD: 2.09, 95% CI: 1.26–3.45;
p = 0.004).

Conclusions: Serum biomarkers may have different roles in prediction of clinical outcomes
among HF patients treated de novo with carvedilol.

Abstract

Background: The role of infl ammatory and hemodynamic stress biomarkers in heart failure
(HF) patients treated de novo with beta-blockers has been poorly studied.

Methods: A total of 86 patients (age 56 ± 9 years, 81 men) with left ventricular ejection fraction
(LVEF) < 40% and previously not treated with beta-blockers were initiated on carvedilol.
At baseline and 12 months later we performed echocardiography, cardiopulmonary exercise
testing, and determined serum levels of B-type natriuretic peptide (BNP), endothelin-1 (ET-1),
C-reactive protein (CRP), interleukin-6, and tumor necrosis factor alpha (TNF -a). Patients
were followed up over a total period of 9 ± 3 years from baseline.

Results: Increased baseline CRP and its on-treatment decrease were associated with improvement
of LVEF (est. coeffi cient per one SD: 1.6; 95% CI: –0.05,3.28; p = 0.056, and –1.80;
–3.43, –0.18; p = 0.030, respectively) and diminishing of LV end-systolic volume index
[mL/m2] (–6.83; –11.32; –2.34; p = 0.003, and 5.85; 1.23; –10.46; p = 0.014, respectively).
Higher baseline ET-1 and on-treatment increase in TNF-a predicted frequent admissions
(> 1) for cardiac complications (odds ratio per one SD: 1.98; 95% CI: 1.09–3.59;
p = 0.025, and 2.07, 1.12–3.84, p = 0.021, respectively) whereas higher baseline BNP was
asociated with increased mortality (hazard ratio per one SD: 2.09, 95% CI: 1.26–3.45;
p = 0.004).

Conclusions: Serum biomarkers may have different roles in prediction of clinical outcomes
among HF patients treated de novo with carvedilol.
Get Citation

Keywords

heart failure, beta-blocker, biological markers, natriuretic peptides, endothelin-1, C-reactive protein

About this article
Title

Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol

Journal

Cardiology Journal

Issue

Vol 20, No 2 (2013)

Pages

144-151

Published online

2013-04-05

DOI

10.5603/CJ.2013.0027

Bibliographic record

Cardiol J 2013;20(2):144-151.

Keywords

heart failure
beta-blocker
biological markers
natriuretic peptides
endothelin-1
C-reactive protein

Authors

Jadwiga Nessler
Bohdan Nessler
Renata Golebiowska-Wiatrak
Ilona Palka
Andrzej Gackowski
Mariusz Kitlinski
Olle Melander
Artur Fedorowski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl